),
Inc. G.R. No. 167715, 17 November 2010
Facts:
Pfizer is the registered owner of a patent pertaining to
Sulbactam Ampicillin. It is marketed under the brand name
Unasyn. Sometime in January and February 2003, Pfizer
discovered that Pharmawealth submitted bids for the supply of
Sulbactam Ampicillin to several hospitals without the Pfizers
consent. Pfizer then demanded that the hospitals cease and
desist from accepting such bids. Pfizer also demanded that
Pharmawealth immediately withdraw its bids to supply
Sulbactam Ampicillin. Pharmawealth and the hospitals ignored
the demands.
Pfizer then filed a complaint for patent infringement with a
prayer for permanent injunction and forfeiture of the infringing
products. A preliminary injunction effective for 90 days was
granted by the IPOs Bureau of Legal Affairs (IPO-BLA). Upon
expiration, a motion for extension filed by Pfizer was denied.
Pfizer filed a Special Civil Action for Certiorari in the Court of
Appeals (CA) assailing the denial.
While the case was pending in the CA, Pfizer filed with the
Regional Trial Court of Makati (RTC) a complaint for
infringement and unfair competition, with a prayer for injunction.
The RTC issued a temporary restraining order, and then a
preliminary injunction.
Pharmawealth filed a motion to dismiss the case in the CA, on
the ground of forum shopping. Nevertheless, the CA issued a
temporary restraining order. Pharmawealth again filed a motion
to dismiss, alleging that the patent, the main basis of the case,
had already lapsed, thus making the case moot, and that the CA
had no jurisdiction to review the order of the IPO-BLA because
this was granted to the Director General. The CA denied all the
motions. Pharmawealth filed a petition for review on Certiorari
with the Supreme Court.
Issues:
a) Can an injunctive relief be issued based on an action of
patent infringement when the patent allegedly infringed has
already lapsed?
Held:
a) No. The provision of R.A. 165, from which the Pfizers patent
was based, clearly states that "[the] patentee shall have the
exclusive right to make, use and sell the patented machine,
article or product, and to use the patented process for the
purpose of industry or commerce, throughout the territory of the
Philippines for the term of the patent; and such making, using,
or selling by any person without the authorization of the
patentee
constitutes
infringement
of
the
patent."
Clearly, the patentees exclusive rights exist only during the
term of the patent. Since the patent was registered on 16 July
1987, it expired, in accordance with the provisions of R.A. 165,
after 17 years, or 16 July 2004. Thus, after 16 July 2004, Pfizer
no longer possessed the exclusive right to make, use, and sell
the products covered by their patent. The CA was wrong in